Sign In
Buy ATHE
$4.42
-0.0800 (-1.78%)
At Close: Jul 31, 2026
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
07:25am, Monday, 30'th Mar 2026
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
03:07am, Thursday, 26'th Mar 2026
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH434, highlighting positive Phase II data in multiple system atrophy (MSA), planned regulatory interact
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
03:50am, Sunday, 15'th Mar 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
07:25am, Monday, 09'th Mar 2026
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –
Head-To-Head Contrast: Alterity Therapeutics (NASDAQ:ATHE) & Athira Pharma (NASDAQ:ATHA)
01:44am, Saturday, 14'th Feb 2026
Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
07:25am, Friday, 30'th Jan 2026
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Down 88.6% in December
03:52am, Wednesday, 14'th Jan 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was sh
Financial Survey: Alterity Therapeutics (NASDAQ:ATHE) and Mesoblast (NASDAQ:MESO)
01:08am, Friday, 02'nd Jan 2026
Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companie
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
07:25am, Wednesday, 12'th Nov 2025
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
07:25am, Friday, 31'st Oct 2025
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neu
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders
07:35am, Thursday, 02'nd Oct 2025
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
07:35am, Monday, 08'th Sep 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to d
Alterity Therapeutics to Present at the Biotech Showcase
07:25am, Tuesday, 02'nd Sep 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
